Document is current
Any future updates will be listed below
-
Authors
Smyth, James W.
Guo, Sujuan
Chaunsali, Lata
O’Rourke, Laurie
Dahlka, Jacob
Deaver, Stacie
Lunski, Michael
Nurmemmedov, Elmar
Sontheimer, Harald https://orcid.org/0000-0002-5843-9871
Sheng, Zhi
Gourdie, Robert G. https://orcid.org/0000-0001-6021-0796
Lamouille, Samy https://orcid.org/0000-0003-2875-494X
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA217503)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (HL161237-02)
- License Information
-
More Information
Article History
Received: 13 April 2024
Revised: 11 February 2025
Accepted: 11 March 2025
First Online: 16 May 2025
Competing interests
: SL is Co-founder and CEO of Acomhal Research Inc, which licensed the JM2 peptide. RGG is Co-founder and CSO of Acomhal Research Inc. SL and RGG have ownership interests in Acomhal Research Inc. The remaining authors have no disclosures to report.
: Patient-derived GSCs provided by Dr. Zhi Sheng and his laboratory were previously isolated from freshly resected GBM tumors in the Department of Neurosurgery, Carilion Clinic, Roanoke, Virginia. The use of these human GBM patient specimens has previously been approved by the Institutional Review Board at the Carilion Clinic and written consent from participating patients [, ]. Patient-derived xenograft (PDX) GBM22 cells provided by Dr. Harald Sontheimer and his laboratory were previously derived from primary brain tumor tissue obtained from a patient who underwent surgical treatment at the Mayo Clinic, with approval from the Mayo Clinic Institutional Review Board and written consent from the participating patient []. All animal procedures were approved and performed in accordance with the ethical guidelines set by the Virginia Tech Institutional Animal Care and Use Committee (IACUC).
